Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.092
Filtrar
1.
BMC Infect Dis ; 24(1): 981, 2024 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-39285366

RESUMO

BACKGROUND: Mycoplasma genitalium (MG), a sexually transmitted infection (STI), has emerged as a common cause of non-gonococcal urethritis and cervicitis worldwide, with documented resistance to commonly used antibiotics including doxycycline and azithromycin. Data in Ghana regarding the prevalence of MG is limited. METHODS: This retrospective study investigated MG presence and macrolide resistance among patients who previously reported to selected clinics for STI symptoms between December 2012 and June 2020. Samples were screened for MG and mutations associated with azithromycin resistance were investigated using Nucleic Acid Amplification Testing (NAAT) including the Resistance Plus MG® kit from SpeeDx and the LightMix® kit for MG, combined with the Modular Mycoplasma Macrolide from TIB Molbiol. RESULTS: A total of 1,015 samples were screened, out of which MG infection rate by TIB Molbiol and SpeeDx were 3.1% and 3.4%, respectively. The mutation responsible for macrolide resistance was detected in one MG positive sample by both assays. Both diagnostic tests revealed no significant association between MG infection and socio-demographic characteristics, clinical symptoms, gonorrhea, and chlamydia infection status. There was no significant difference in the mycoplasma percentage positivity rate detected using SpeeDx (3.4%) and TIB Molbiol (3.1%). CONCLUSIONS: While not commonly tested as a cause of STI symptoms, MG is widespread in Ghana, exhibiting symptoms and prevalence comparable to those in other countries and linked to antimicrobial resistance. Future research using various molecular techniques is essential to monitor resistance trends and guide future antibiotic choices.


Assuntos
Antibacterianos , Farmacorresistência Bacteriana , Macrolídeos , Infecções por Mycoplasma , Mycoplasma genitalium , Mycoplasma genitalium/efeitos dos fármacos , Mycoplasma genitalium/genética , Mycoplasma genitalium/isolamento & purificação , Humanos , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/microbiologia , Gana/epidemiologia , Feminino , Masculino , Adulto , Estudos Retrospectivos , Prevalência , Macrolídeos/farmacologia , Macrolídeos/uso terapêutico , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Farmacorresistência Bacteriana/genética , Adulto Jovem , Adolescente , Pessoa de Meia-Idade , Saúde Sexual , Azitromicina/farmacologia , Azitromicina/uso terapêutico , Mutação , Testes de Sensibilidade Microbiana
2.
Front Cell Infect Microbiol ; 14: 1407124, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39119297

RESUMO

Introduction: This study aims to determine the etiological, sociodemographic, and clinical characteristics of STIs, and the level of resistance in M. genitalium in Shenzhen, a representative first-tier city of southern China. Methods: A multicenter cross-sectional study was conducted and 7886 sexually active participants attending STI-related departments were involved from 22 hospitals. Nine STI-related organisms including N. gonorrhoeae, C. trachomatis, T. vaginalis, M. genitalium, HSV-1, HSV-2, M. hominis, U. parvum, and U. urealyticum were screened. Results: Being single or divorced was associated with increased detection of N. gonorrhoeae, C. trachomatis, M. genitalium, HSV-1, HSV-2 and M. hominis. Lower education level was associated with increased detection of C. trachomatis, HSV-2 and M. hominis. No insurance coverage was an independent risk factor for T. vaginalis, M. hominis and U. parvum positivity. Three resistance-determining regions related to macrolide and fluoroquinolone were sequenced in 154 M. genitalium positive samples, among which 90.3% harbored mutations related to macrolide or fluroquinolone resistance and 67.5% were multidrug-resistant M. genitalium. A2072G in 23S rRNA and Ser83Ile in parC were the most common mutations. M. hominis was associated with manifestations of bacterial vaginosis in female and epididymitis in male. Conclusions: Single or divorced individuals, those with lower education level and individuals without insurance are higher-risk key populations for STIs. The prevalence of antimicrobial-resistant M. genitalium in Shenzhen is high. Detection of M. hominis increased significantly with lower education level and no health insurance coverage, and it is associated with bacterial vaginosis or epididymitis, indicating that M. hominis deserves further attention.


Assuntos
Antibacterianos , Mycoplasma genitalium , Infecções Sexualmente Transmissíveis , Humanos , Estudos Transversais , China/epidemiologia , Feminino , Masculino , Adulto , Mycoplasma genitalium/genética , Mycoplasma genitalium/isolamento & purificação , Mycoplasma genitalium/efeitos dos fármacos , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/microbiologia , Adulto Jovem , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Pessoa de Meia-Idade , Farmacorresistência Bacteriana , Adolescente , Fatores de Risco , Fatores Socioeconômicos , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/microbiologia , Testes de Sensibilidade Microbiana , Prevalência
3.
J Clin Microbiol ; 62(9): e0081624, 2024 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-39140739

RESUMO

Significant increases in rates of sexually transmitted infections (STIs) caused by Trichomonas vaginalis (TV), Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) are occurring in the United States. We present results of a U.S. study examining the intersection of STIs and vaginitis. Among 1,051 women with diagnoses for the presence or absence of bacterial vaginosis (BV) and/or symptomatic vulvovaginal candidiasis (VVC), 195 (18.5%) had one or more STIs, including 101 (9.6%) with TV, 24 (2.3%) with CT, 9 (0.8%) with NG, and 93 (8.8%) with MG. STI prevalence in BV-positive women was 26.3% (136/518), significantly higher than STI prevalence of 12.5% (59/474) in BV-negative women (P < 0.0002). Unlike infections with CT or NG, solo infections of MG or TV were each significantly associated with a diagnosis of BV-positive/VVC-negative (OR 3.0751; 95% CI 1.5797-5.9858, P = 0.0113, and OR 2.873; 95% CI 1.5687-5.2619, P = 0.0017, respectively) and with mixed infections containing MG and TV (OR 3.4886; 95% CI 1.8901-6.439, P = 0.0042, and OR 3.1858; 95% CI 1.809-5.6103, P = 0.0014, respectively). TV and MG infection rates were higher in all Nugent score (NS) categories than CT and NG infection rates; however, both STIs had similar comparative prevalence ratios to CT in NS 6-10 vs NS 0-5 (CT: 3.06% vs 1.4%, 2.2-fold; MG: 10.7% vs 6.1%, 1.8-fold; TV: 14.5% vs 7.0%, 2.1-fold). NG prevalence was relatively invariant by the NS category. These results highlight the complexity of associations of STIs with two major causes of vaginitis and underscore the importance of STI testing in women seeking care for abnormal vaginal discharge and inflammation. IMPORTANCE: This study reports high rates for sexually transmitted infections (STIs) in women seeking care for symptoms of vaginitis and bacterial vaginosis, revealing highly complex associations of STIs with two of the major causes of vaginal dysbiosis. These results underscore the importance of STI testing in women seeking care for abnormal vaginal discharge and inflammation.


Assuntos
Técnicas de Amplificação de Ácido Nucleico , Infecções Sexualmente Transmissíveis , Humanos , Feminino , Estados Unidos/epidemiologia , Adulto , Adulto Jovem , Prevalência , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/microbiologia , Técnicas de Amplificação de Ácido Nucleico/métodos , Adolescente , Pessoa de Meia-Idade , Mycoplasma genitalium/genética , Mycoplasma genitalium/isolamento & purificação , Vaginite/epidemiologia , Vaginite/microbiologia , Trichomonas vaginalis/genética , Trichomonas vaginalis/isolamento & purificação , Vaginose Bacteriana/epidemiologia , Vaginose Bacteriana/diagnóstico , Vaginose Bacteriana/microbiologia , Chlamydia trachomatis/genética , Chlamydia trachomatis/isolamento & purificação , Candidíase Vulvovaginal/epidemiologia , Candidíase Vulvovaginal/diagnóstico , Candidíase Vulvovaginal/microbiologia , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/diagnóstico , Infecções por Mycoplasma/microbiologia , Neisseria gonorrhoeae/genética , Neisseria gonorrhoeae/isolamento & purificação
4.
Microb Pathog ; 195: 106872, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39173852

RESUMO

Membrane lipoproteins serve as primary pro-inflammatory virulence factors in Mycoplasma genitalium. Membrane lipoproteins primarily induce inflammatory responses by activating Toll-like Receptor 2 (TLR2); however, the role of the metabolic status of urethral epithelial cells in inflammatory response remains unclear. In this study, we found that treatment of uroepithelial cell lines with M. genitalium membrane lipoprotein induced metabolic reprogramming, characterized by increased aerobic glycolysis, decreased oxidative phosphorylation, and increased production of the metabolic intermediates acetyl-CoA and malonyl-CoA. The metabolic shift induced by membrane lipoproteins is reversible upon blocking MyD88 and TRAM. Malonyl-CoA induces malonylation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and malonylated GAPDH could dissociate from the 3' untranslated region of TNF-α and IFN-γ mRNA. This dissociation greatly reduces the inhibitory effect on the translation of TNF-α and IFN-γ mRNA, thus achieving fine-tuning control over cytokine secretion. These findings suggest that GAPDH malonylation following M. genitalium infection is an important inflammatory signal that plays a crucial role in urogenital inflammatory diseases.


Assuntos
Citocinas , Células Epiteliais , Interferon gama , Mycoplasma genitalium , Fator de Necrose Tumoral alfa , Mycoplasma genitalium/metabolismo , Mycoplasma genitalium/genética , Células Epiteliais/metabolismo , Células Epiteliais/microbiologia , Humanos , Citocinas/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Interferon gama/metabolismo , Linhagem Celular , Lipoproteínas/metabolismo , Gliceraldeído-3-Fosfato Desidrogenases/metabolismo , Gliceraldeído-3-Fosfato Desidrogenases/genética , Uretra/microbiologia , Uretra/metabolismo , Infecções por Mycoplasma/metabolismo , Infecções por Mycoplasma/microbiologia , Fatores de Virulência/metabolismo , Fator 88 de Diferenciação Mieloide/metabolismo , Glicólise , Receptor 2 Toll-Like/metabolismo , Receptor 2 Toll-Like/genética
5.
J Med Virol ; 96(8): e29852, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39166456

RESUMO

The association between human papillomavirus (HPV) and other sexually transmitted infections (STIs) in anal lesions still remains unclear. Aim of the study was to evaluate the prevalence of simultaneous infection of HPV and Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis in individuals screened for HPV anal infection. A total of 507 anal samples were tested for both anal HPV and STIs: 16% resulted positive for one or more non-HPV STIs. Specifically, C. trachomatis, M. genitalium, and N. gonorrhoeae were detected in 8%, 5%, and 4% of cases, respectively. Two groups were considered, including a positive STI group and a negative STI group. The prevalence of HPV was similar in patients in both groups: high risk (HR)-HPV and low risk (LR)-HPV were 67% and 53% versus 62% (p = 0.361) and 54% (p = 0.864) of patients, respectively. However, HPV 16, 18, 35, 51, 59, and 69 were significantly more frequent in patients tested positive for other STIs versus HPV infection alone (p < 0.05). No significant differences between the two groups were observed in vaccination coverage, 28% versus 32% (p = 0.463), and HIV status, 86% versus 84% (p = 0.658). The study shows that the overall HPV status is not directly correlated to other STIs in the investigated population, except for certain HPV types, including HR-HPV 16, reinforcing the urge for a greater vaccination coverage.


Assuntos
Coinfecção , Infecções por Papillomavirus , Infecções Sexualmente Transmissíveis , Humanos , Feminino , Prevalência , Adulto , Masculino , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/virologia , Pessoa de Meia-Idade , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/virologia , Adulto Jovem , Coinfecção/epidemiologia , Coinfecção/virologia , Adolescente , Canal Anal/virologia , Canal Anal/microbiologia , Mycoplasma genitalium/isolamento & purificação , Papillomaviridae/isolamento & purificação , Papillomaviridae/genética , Papillomaviridae/classificação , Idoso , Chlamydia trachomatis/isolamento & purificação , Gonorreia/epidemiologia , Infecções por Chlamydia/epidemiologia , Infecções por Chlamydia/microbiologia , Trichomonas vaginalis/isolamento & purificação , Infecções por Mycoplasma/epidemiologia , Neisseria gonorrhoeae/isolamento & purificação
6.
Artigo em Inglês | MEDLINE | ID: mdl-39165019

RESUMO

Abstract: The Northern Territory (NT) has the highest rates of sexually transmitted infections (STI) in Australia; however, the local prevalence of Mycoplasma genitalium (M. genitalium) has not been previously determined. This study was designed to review M. genitalium detection, to determine the regional NT prevalence and macrolide resistance rates. In our study the NT background prevalence of M. genitalium is 13%, with the highest detection rates occurring in central Australia and in correctional facility inmates. Symptomatic patients attending sexual health clinics have a positivity rate of 12%, but very high macrolide resistance. The decision to screen for M. genitalium should be based on several factors, including the prevalence of the infection in the local population; the availability of effective treatments; and the potential benefits and risks of detection and therapy.


Assuntos
Infecções por Mycoplasma , Mycoplasma genitalium , Humanos , Mycoplasma genitalium/isolamento & purificação , Northern Territory/epidemiologia , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/microbiologia , Estudos Retrospectivos , Prevalência , Masculino , Feminino , Adulto , Antibacterianos/farmacologia , Farmacorresistência Bacteriana , Pessoa de Meia-Idade , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/microbiologia , Adulto Jovem , Macrolídeos/farmacologia
7.
J Nat Prod ; 87(7): 1746-1753, 2024 Jul 26.
Artigo em Inglês | MEDLINE | ID: mdl-38958274

RESUMO

Mycoplasma genitalium is a sexually transmitted bacterium associated with urogenital disease syndromes in the US and worldwide. The global rise in drug resistance in M. genitalium necessitates the development of novel drugs to treat this pathogen. To address this need, we have screened extracts from a library of fungal isolates assembled through the University of Oklahoma Citizen Science Soil Collection Program. Analysis of one of the bioactive extracts using bioassay-guided fractionation led to the purification of the compound PF1140 (1) along with a new and several other known pyridones. The N-hydroxy pyridones are generally regarded as siderophores with high binding affinity for iron(III) under physiological conditions. Results from UV-vis absorption spectroscopy-based titration experiments revealed that 1 complexes with Fe3+. As M. genitalium does not utilize iron, we propose that the PF1140-iron complex induces cytotoxicity by facilitating the cellular uptake of iron, which reacts with endogenous hydrogen peroxide to produce toxic hydroxyl radicals.


Assuntos
Ferro , Mycoplasma genitalium , Mycoplasma genitalium/metabolismo , Mycoplasma genitalium/efeitos dos fármacos , Ferro/metabolismo , Estrutura Molecular , Testes de Sensibilidade Microbiana , Antibacterianos/farmacologia , Antibacterianos/química , Piridonas/farmacologia , Piridonas/química , Fungos/química , Fungos/metabolismo , Compostos Férricos/química , Peróxido de Hidrogênio , Sideróforos/farmacologia , Sideróforos/química
8.
Med ; 5(9): 1123-1136.e3, 2024 Sep 13.
Artigo em Inglês | MEDLINE | ID: mdl-38870930

RESUMO

BACKGROUND: Mycoplasma genitalium infection in pregnancy is increasingly reported at similar frequencies to other sexually transmitted infections (STIs). Knowledge on its contribution to adverse pregnancy outcomes is very limited, especially relative to other STIs or bacterial vaginosis (BV). Whether M. genitalium influences birthweight remains unanswered. METHODS: Associations between birthweight and M. genitalium and other STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis) and BV in pregnancy were examined in 416 maternal-newborn pairs from a prospective cohort study in Papua New Guinea. FINDINGS: Compared to uninfected women, M. genitalium (-166.9 g, 95% confidence interval [CI]: -324.2 to -9.7 g, p = 0.038) and N. gonorrhoeae (-274.7 g, 95% CI: -561.9 to 12.5 g, p = 0.061) infections were associated with lower birthweight in an adjusted analysis. The association for C. trachomatis was less clear, and T. vaginalis and BV were not associated with lower birthweight. STI prevalence was high for M. genitalium (13.9%), N. gonorrhoeae (5.0%), and C. trachomatis (20.0%); co-infections were frequent. Larger effect sizes on birthweight occurred with co-infections of M. genitalium, N. gonorrhoeae, and/or C. trachomatis. CONCLUSION: M. genitalium is a potential contributor to lower birthweight, and co-infections appear to have a greater negative impact on birthweight. Trials examining the impact of early diagnosis and treatment of M. genitalium and other STIs in pregnancy and preconception are urgently needed. FUNDING: Funding was received from philanthropic grants, the National Health and Medical Research Council, and the Burnet Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


Assuntos
Coinfecção , Infecções por Mycoplasma , Mycoplasma genitalium , Complicações Infecciosas na Gravidez , Humanos , Feminino , Mycoplasma genitalium/isolamento & purificação , Gravidez , Infecções por Mycoplasma/epidemiologia , Estudos Prospectivos , Coinfecção/epidemiologia , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/microbiologia , Adulto , Recém-Nascido , Papua Nova Guiné/epidemiologia , Recém-Nascido de Baixo Peso , Vaginose Bacteriana/epidemiologia , Vaginose Bacteriana/microbiologia , Peso ao Nascer , Adulto Jovem , Prevalência , Gonorreia/epidemiologia
9.
J Infect Public Health ; 17(7): 102447, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38824739

RESUMO

BACKGROUND: Current clinical care for common bacterial STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG)) involves empiric antimicrobial therapy when clients are symptomatic, or if asymptomatic, waiting for laboratory testing and recall if indicated. Near-to-patient testing (NPT) can improve pathogen-specific prescribing and reduce unnecessary or inappropriate antibiotic use in treating sexually transmitted infections (STI) by providing same-day delivery of results and treatment. METHODS: We compared the economic cost of NPT to current clinic practice for managing clients with suspected proctitis, non-gonococcal urethritis (NGU), or as an STI contact, from a health provider's perspective. With a microsimulation of 1000 clients, we calculated the cost per client tested and per STI- and pathogen- detected for each testing strategy. Sensitivity analyses were conducted to assess the robustness of the main outcomes. Costs are reported as Australian dollars (2023). RESULTS: In the standard care arm, cost per client tested for proctitis, NGU in men who have sex with men (MSM) and heterosexual men were the highest at $247.96 (95% Prediction Interval (PI): 246.77-249.15), $204.23 (95% PI: 202.70-205.75) and $195.01 (95% PI: 193.81-196.21) respectively. Comparatively, in the NPT arm, it costs $162.36 (95% PI: 161.43-163.28), $158.39 (95% PI: 157.62-159.15) and $149.17 (95% PI: 148.62-149.73), respectively. Using NPT resulted in cost savings of 34.52%, 22.45% and 23.51%, respectively. Among all the testing strategies, substantial difference in cost per client tested between the standard care arm and the NPT arm was observed for contacts of CT or NG, varying from 27.37% to 35.28%. CONCLUSION: We found that NPT is cost-saving compared with standard clinical care for individuals with STI symptoms and sexual contacts of CT, NG, and MG.


Assuntos
Infecções Sexualmente Transmissíveis , Humanos , Masculino , Feminino , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/economia , Infecções Sexualmente Transmissíveis/tratamento farmacológico , Gonorreia/diagnóstico , Gonorreia/economia , Gonorreia/tratamento farmacológico , Austrália , Adulto , Análise Custo-Benefício , Infecções por Chlamydia/diagnóstico , Infecções por Chlamydia/economia , Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis , Neisseria gonorrhoeae/isolamento & purificação , Mycoplasma genitalium , Programas de Rastreamento/economia , Programas de Rastreamento/métodos , Infecções por Mycoplasma/diagnóstico , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/economia , Uretrite/diagnóstico , Uretrite/economia , Uretrite/tratamento farmacológico , Uretrite/microbiologia
10.
Sci Rep ; 14(1): 12856, 2024 06 04.
Artigo em Inglês | MEDLINE | ID: mdl-38834637

RESUMO

The recommended first-line treatment for Mycoplasma genitalium infections is azithromycin. However, the prevalence of macrolide resistance for M. genitalium has increased to more than 50% worldwide. In 2013, Australia introduced a resistance-guided therapy (RGT) strategy to manage M. genitalium infections. This study assesses the cost-effectiveness of the RGT approach compared to no RGT (i.e., without macrolide resistance profile test) in women, men who have sex with men (MSM), and men who have sex with women (MSW) in Australia. We constructed dynamic transmission models of M. genitalium infections in women, MSM, and MSW in Australia, each with a population of 100,000. These models compared the costs and quality-adjusted life-years (QALYs) gained between RGT and no RGT scenarios from a healthcare perspective over ten years. All costs are reported in 2022 Australian dollars (Australian $). In our model, RGT is cost saving in women and MSM, with the incremental net monetary benefit of $1.3 million and $17.9 million, respectively. In MSW, the RGT approach is not cost-effective, with an incremental cost-effectiveness ratio of -$106.96 per QALY gained. RGT is cost saving compared to no RGT for M. genitalium infections in women and MSM, supporting its adoption as the national management strategy for these two population groups.


Assuntos
Antibacterianos , Análise Custo-Benefício , Farmacorresistência Bacteriana , Infecções por Mycoplasma , Mycoplasma genitalium , Mycoplasma genitalium/efeitos dos fármacos , Humanos , Austrália/epidemiologia , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/economia , Infecções por Mycoplasma/microbiologia , Feminino , Masculino , Antibacterianos/uso terapêutico , Antibacterianos/economia , Antibacterianos/farmacologia , Azitromicina/uso terapêutico , Azitromicina/economia , Anos de Vida Ajustados por Qualidade de Vida , Adulto , Macrolídeos/uso terapêutico , Macrolídeos/economia
11.
Indian J Dermatol Venereol Leprol ; 90(5): 632-635, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38899414

RESUMO

Background Increasing rates of macrolide and fluroquinolone resistance in Mycoplasma genitalium (MG) are being reported worldwide with resultant treatment failure. Aim We aimed to determine the level of antibiotic resistance of MG in men who have sex with men (MSM) attending a sexually transmitted infections (STIs) clinic in New Delhi, India. Methods Real-time polymerase chain reaction (PCR) assays targeting MgPa and pdhD genes were performed to detect MG rectal, urogenital or oropharyngeal infections in 180 MSM between January 2022 and June 2023. Macrolide resistance-associated mutations (MRM) and quinolone resistance-associated mutations (QRM) were detected by specific amplification of domain V of 23SrRNA gene and appropriate regions of parC and gyrA genes respectively followed by sequencing. PCR-based screening for Chlamydia trachomatis (CT) infection was also performed. Results A total of 13 (7.2%) MSM were positive for MG infection. The most common site of infection was anorectum (8/13; 61.5%) followed by the urethra (5/13; 38.5%). None of the patients had infection at both the sites, and no oropharyngeal MG infection was detected. CT infection was detected in 37 (20.6%) MSM. Of the 13 MG-infected MSM, 6 (46.2%) were co-infected with CT. MRM and QRM were found in five (46.2%) and two (15.4%) strains, respectively. Both Quinolone resistance mutation (QRM)-harbouring strains also harboured MRM. All the five MG isolates carried the MRM A2071G. Both the QRM isolates co-harboured the parC and gyrA single-nucleotide polymorphisms. There was no correlation between the presence of antibiotic resistance and co-infection with CT (P = 0.52). Limitation Because all patients in the study were MSM, the high rate of resistance to macrolides and fluoroquinolones could not be extrapolated for non-MSM patients. Conclusion This is a report of an initial survey of antibiotic resistance to MG in a country where its diagnosis and treatment are not routinely available. We found a high prevalence of MG-carrying MRM, QRM and dual-class resistance in MSM in the absence of antibiotic exposure. This study mandates the need for both screening and detection of antimicrobial resistance against MG.


Assuntos
Antibacterianos , Farmacorresistência Bacteriana , Fluoroquinolonas , Macrolídeos , Mutação , Infecções por Mycoplasma , Mycoplasma genitalium , Humanos , Mycoplasma genitalium/genética , Mycoplasma genitalium/efeitos dos fármacos , Masculino , Fluoroquinolonas/farmacologia , Fluoroquinolonas/uso terapêutico , Projetos Piloto , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/microbiologia , Índia/epidemiologia , Adulto , Farmacorresistência Bacteriana/genética , Macrolídeos/farmacologia , Macrolídeos/uso terapêutico , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Homossexualidade Masculina , Adulto Jovem , Pessoa de Meia-Idade
12.
J Microbiol Immunol Infect ; 57(4): 629-637, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38777653

RESUMO

BACKGROUND: Mycoplasma genitalium is an emerging etiology of sexually transmitted infections (STIs) with increasing resistance to antimicrobials. Surveillance on the epidemiology of M. genitalium infection and antimicrobial resistance is warranted. METHODS: Between September 2021 and August 2023, people with HIV (PWH) and people without HIV (PWoH) at risk of STIs were screened for M. genitalium infection using a multiplex polymerase-chain-reaction assay of specimens collected from the rectum, urethra, oral cavity, and vagina. The prevalences of resistance-associated mutations (RAMs) of M. genitalium to fluoroquinolones, macrolides, and tetracycline were investigated. RESULTS: During the 2-year study period, 1021 participants were enrolled, including 531 PWH and 490 PWoH. Overall, 83 (8.1%) and 34 (7.6%) participants had M. genitalium infection at baseline and during follow-up, respectively, with the rectum being the most common site of detection (61.5%). With the first course of antimicrobial treatment, 27 of 63 (42.9%) participants with M. genitalium infection were cured during follow-up, including 24 of 58 (41.4%) who received doxycycline monotherapy. The prevalence of RAMs to macrolides, fluoroquinolones, and tetracyclines at baseline were 24.3%, 22.4%, and 7.9%, respectively. Though PWH had more M. genitalium infection (10.2% vs 5.9%, p = 0.01), a higher rate of RAMs to macrolides (41.0% vs 14.7%, p < 0.01) was found in PWoH. CONCLUSIONS: Among high-risk populations, the prevalence of M. genitalium infection was 8.1%. The overall genotypic resistance of M. genitalium to macrolides and fluoroquinolones was moderately high in Taiwan. Detection of M. genitalium infection and antimicrobial resistance is warranted to ensure resistance-guided antimicrobial treatments to be administered.


Assuntos
Antibacterianos , Farmacorresistência Bacteriana , Fluoroquinolonas , Macrolídeos , Mutação , Infecções por Mycoplasma , Mycoplasma genitalium , Humanos , Mycoplasma genitalium/genética , Mycoplasma genitalium/efeitos dos fármacos , Mycoplasma genitalium/isolamento & purificação , Macrolídeos/farmacologia , Macrolídeos/uso terapêutico , Taiwan/epidemiologia , Fluoroquinolonas/farmacologia , Fluoroquinolonas/uso terapêutico , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/microbiologia , Feminino , Masculino , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Adulto , Farmacorresistência Bacteriana/genética , Prevalência , Pessoa de Meia-Idade , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Testes de Sensibilidade Microbiana
13.
Rev Clin Esp (Barc) ; 224(6): 393-397, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38701969

RESUMO

INTRODUCTION: The global increase in sexual transmitted infections (STI) makes it necessary to seek public health strategies that facilitate rapid and minimally invasive diagnosis. The objective was to evaluate the concordance between vaginal and endocervical samples for STI diagnosis. MATERIALS AND METHODS: A retrospective cross-sectional study was carried out on vaginal and endocervical samples from women attended in our reference area with symptoms suggestive of vulvovaginitis or for STI screening during the study period. RESULTS: A total of 130 paired samples were analyzed; fifty-seven and 59 samples were positive for vaginal and endocervical specimens (Kappa index of 0.969 (Standard error = 0.022). The sensitivity of the vaginal samples was 96.5% (IC95%: 87.2-99.4), with a specificity of 100% (IC95%: 93.0-100). DISCUSSION: The introduction of STI screening in vaginal samples in our environment can facilitate rapid and effective diagnosis and allow early treatment of STI. Additionally, it facilitates sample collection and diagnosis in the community setting, essential for optimal screening.


Assuntos
Infecções por Chlamydia , Gonorreia , Mycoplasma genitalium , Manejo de Espécimes , Humanos , Feminino , Estudos Transversais , Estudos Retrospectivos , Adulto , Espanha , Gonorreia/diagnóstico , Infecções por Chlamydia/diagnóstico , Mycoplasma genitalium/isolamento & purificação , Manejo de Espécimes/métodos , Adulto Jovem , Infecções por Mycoplasma/diagnóstico , Sensibilidade e Especificidade , Colo do Útero/microbiologia , Colo do Útero/patologia , Esfregaço Vaginal , Vagina/microbiologia , Pessoa de Meia-Idade , Tricomoníase/diagnóstico , Adolescente , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/microbiologia
14.
Biosensors (Basel) ; 14(5)2024 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-38785734

RESUMO

Sexually transmitted diseases (STDs) are a global concern because approximately 1 million new cases emerge daily. Most STDs are curable, but if left untreated, they can cause severe long-term health implications, including infertility and even death. Therefore, a test enabling rapid and accurate screening and genotyping of STD pathogens is highly awaited. Herein, we present the development of the DNA-based 6STD Genotyping 9G Membrane test, a lateral flow strip membrane assay, for the detection and genotyping of six STD pathogens, including Trichomonas vaginalis, Ureaplasma urealyticum, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Mycoplasma genitalium. Here, we developed a multiplex PCR primer set that allows PCR amplification of genomic materials for these six STD pathogens. We also developed the six ssDNA probes that allow highly efficient detection of the six STD pathogens. The 6STD Genotyping 9G Membrane test lets us obtain the final detection and genotyping results in less than 30 m after PCR at 25 °C. The accuracy of the 6STD Genotyping 9G membrane test in STD genotyping was confirmed by its 100% concordance with the sequencing results of 120 clinical samples. Therefore, the 6STD Genotyping 9G Membrane test emerges as a promising diagnostic tool for precise STD genotyping, facilitating informed decision-making in clinical practice.


Assuntos
Chlamydia trachomatis , Genótipo , Neisseria gonorrhoeae , Infecções Sexualmente Transmissíveis , Humanos , Chlamydia trachomatis/genética , Chlamydia trachomatis/isolamento & purificação , Neisseria gonorrhoeae/genética , Neisseria gonorrhoeae/isolamento & purificação , Infecções Sexualmente Transmissíveis/microbiologia , Infecções Sexualmente Transmissíveis/diagnóstico , Trichomonas vaginalis/genética , Trichomonas vaginalis/isolamento & purificação , Técnicas de Genotipagem , Mycoplasma hominis/isolamento & purificação , Mycoplasma hominis/genética , Ureaplasma urealyticum/genética , Ureaplasma urealyticum/isolamento & purificação , DNA , Mycoplasma genitalium/genética , Mycoplasma genitalium/isolamento & purificação , Técnicas Biossensoriais , DNA Bacteriano/análise , Reação em Cadeia da Polimerase Multiplex/métodos
15.
J Clin Microbiol ; 62(6): e0048524, 2024 Jun 12.
Artigo em Inglês | MEDLINE | ID: mdl-38785449

RESUMO

A laboratory-developed test (LDT) using analyte-specific reagents has been optimized on a commercial platform to detect macrolide resistance-associated mutations (MRM) in 23S rRNA from Mycoplasmoides genitalium from primary clinical specimens. In this study, MRM-LDT was applied to a multi-specimen source study set. One thousand four hundred ninety-five primary specimens testing positive for M. genitalium by commercial transcription-mediated amplification (TMA) were initially titered by the TMA assay using serial 10-fold dilutions to semi-quantitate target nucleic acid burden. Primary specimens were then processed for MRM detection using the MRM-LDT. Findings were stratified by gender and specimen source. The mean log10 target nucleic acid titer of a TMA-positive specimen was 3.51 (median 3; range 0-10). Male specimens (n = 1145) demonstrated a mean log10 M. genitalium TMA titer of 3.67; that value observed in 350 female specimens was 2.98 (P < 0.0001). The MRM-LDT detection rate (88.7%) from specimens with log10 M. genitalium TMA titers ≥ 4 was increased over specimens with log10 titers ≤ 1 (4.5%; P < 0.0002). In females, MRM-LDT was positive from 51.3% of vaginal swab and 34.7% of urine specimens (P = 0.01). In males, MRM-LDT was positive from 65.0% of rectal swab and 55.7% of urine specimens (P = 0.002). Differences were also observed in log10 M. genitalium TMA titers as a function of specimen source. M. genitalium macrolide resistance rates among multiple specimen sources, as determined by MRM-LDT, are high in the United States and can be consistent with target nucleic acid burden within the primary specimen. Caveats experienced within subgroupings support MRM reflex testing on primary M. genitalium-positive specimens. IMPORTANCE: First-line macrolide treatment failure is of increasing concern with Mycoplasmoides genitalium in multiple settings. Recent sexually-transmitted infection treatment guidelines from the United States Centers for Disease Control and Prevention have predicated therapeutic approaches on the availability of a macrolide resistance/susceptibility result from a primary clinical specimen. In this report, we investigate potential correlation between macrolide resistance mutation detection rates (identified by a molecular amplified laboratory-developed test) and transcription-mediated amplification-based rRNA target semi-quantitation. Data reveal that rRNA semi-quantitation and laboratory-developed test detection rate differences exist as a function of gender and specimen source. These data can guide providers in proper specimen selection not only for the laboratory diagnosis of M. genitalium but also macrolide resistance mutation determination from primary clinical specimens.


Assuntos
Farmacorresistência Bacteriana , Macrolídeos , RNA Ribossômico 23S , Humanos , Feminino , Masculino , Macrolídeos/farmacologia , RNA Ribossômico 23S/genética , Farmacorresistência Bacteriana/genética , Fatores Sexuais , Antibacterianos/farmacologia , Mycoplasma genitalium/genética , Mycoplasma genitalium/efeitos dos fármacos , Técnicas de Diagnóstico Molecular/métodos , Mutação
16.
Int J STD AIDS ; 35(9): 696-702, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38659325

RESUMO

BACKGROUND: Sexually transmitted infections (STIs) may cause substantial individual suffering and a large economic burden for society. This study examined the seroprevalence of Chlamydia trachomatis, Mycoplasma genitalium, herpes simplex virus (HSV) types 1 and 2, and several human papillomaviruses (HPV) in the Swedish population over time. METHODS: The study population consisted of 30-year-old women attending maternity care, and 50 year-old men and women attending health check-ups, from 1975 to 2018. Antibody status was determined by multiplex serology and quantified using median reporter fluorescence intensity (MFI). RESULTS: A total of 891 samples were analysed (519 from 30-year-old women, 186 from 50 year-old women and 186 from 50 year-old men). Of these, 41.5% showed seropositivity for Chlamydia trachomatis, 16.7% for Mycoplasma genitalium, 70.5% for HSV-1, 14.9% for HSV-2, 13.2% for high-risk HPV, and 8.3% for low-risk HPV. Seropositivity for Mycoplasma genitalium, HSV-1 and especially Chlamydia trachomatis decreased over time. CONCLUSIONS: There was a decrease over time in Chlamydia trachomatis seroprevalence, probably due to contact tracing, testing and early treatment; this might also have affected Mycoplasma genitalium seroprevalence. Despite the reduction, seroprevalences are still high, so continued and new efforts to reduce STI incidence are essential.


Assuntos
Infecções por Chlamydia , Chlamydia trachomatis , Mycoplasma genitalium , Infecções Sexualmente Transmissíveis , Humanos , Estudos Soroepidemiológicos , Feminino , Estudos Transversais , Adulto , Suécia/epidemiologia , Pessoa de Meia-Idade , Infecções Sexualmente Transmissíveis/epidemiologia , Masculino , Chlamydia trachomatis/isolamento & purificação , Chlamydia trachomatis/imunologia , Infecções por Chlamydia/epidemiologia , Mycoplasma genitalium/isolamento & purificação , Herpesvirus Humano 1/imunologia , Infecções por Papillomavirus/epidemiologia , Infecções por Mycoplasma/epidemiologia , Herpes Genital/epidemiologia , Herpesvirus Humano 2/imunologia , Herpesvirus Humano 2/isolamento & purificação , Anticorpos Antivirais/sangue , Anticorpos Antibacterianos/sangue , Papillomaviridae/imunologia , Papillomaviridae/isolamento & purificação
17.
Rev Esp Quimioter ; 37(3): 270-273, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38591493

RESUMO

OBJECTIVE: Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area. METHODS: A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG-AziR Assay and AllplexTM MG-MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene. RESULTS: A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%). CONCLUSIONS: The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.


Assuntos
Antibacterianos , Azitromicina , Farmacorresistência Bacteriana , Moxifloxacina , Mutação , Infecções por Mycoplasma , Mycoplasma genitalium , Mycoplasma genitalium/efeitos dos fármacos , Mycoplasma genitalium/genética , Moxifloxacina/farmacologia , Moxifloxacina/uso terapêutico , Azitromicina/farmacologia , Azitromicina/uso terapêutico , Espanha , Humanos , Estudos Prospectivos , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Farmacorresistência Bacteriana/genética , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/microbiologia , Feminino , Masculino , Testes de Sensibilidade Microbiana , RNA Ribossômico 23S/genética , Adulto , DNA Topoisomerase IV/genética
18.
Int J Gynaecol Obstet ; 166(1): 62-70, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38573181

RESUMO

OBJECTIVE: There is a high prevalence and incidence rate of asymptomatic sexually transmitted infections (STIs) during pregnancy in adolescent girls and young women in Africa. The association between STIs and pregnancy outcomes in a hyperepidemic HIV setting has not been well described. METHODS: Pregnant women, HIV-1 negative and <28 weeks' gestation at three primary health clinics in KwaZulu-Natal, South Africa were enrolled from February 2017 to March 2018. Vaginal swabs collected at the first and later antenatal visits were stored and retrospectively tested for HSV-2, Trichomonas vaginalis, Chlamydia trachomatis and Neisseria gonorrhoeae at the end of the study. The association between STIs detected at first and later antenatal visits and pregnancy outcome was assessed using multivariable logistic regression models adjusted for maternal age and treatment received for symptomatic STIs. RESULTS: Testing positive Mycoplasma genitalium at the first antenatal visit was significantly associated with low birth weight (odds ratio [OR] 5.22; 95% confidence interval [CI]: 1.10-15.98). Testing positive for T. vaginalis at the repeat visit was significantly associated with preterm births (OR 2.37; 95% CI: 1.11-5.03), low birth weight (OR 2.56; 1.16-5.63) and a composite adverse pregnancy outcome (OR 2.11; 95% CI: 1.09-4.08). Testing positive for HSV-2 at the repeat visit was also likely associated with experiencing a preterm birth or any adverse pregnancy outcome (OR 3.39; 95% CI: 0.86-13.3) (P = 0.096). CONCLUSIONS: Among predominantly asymptomatic STIs, M. genitalium detected at baseline visit was significantly associated with low birth weight, while T. vaginalis detected at the repeat visit in later pregnancy was significantly associated with preterm birth. Further research is warranted to study the impact of etiological testing of STIs at more than one antenatal visit and empirical treatment on pregnancy outcomes.


Assuntos
Complicações Infecciosas na Gravidez , Resultado da Gravidez , Nascimento Prematuro , Infecções Sexualmente Transmissíveis , Humanos , Feminino , Gravidez , Estudos Retrospectivos , Complicações Infecciosas na Gravidez/epidemiologia , África do Sul/epidemiologia , Adulto , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/diagnóstico , Adulto Jovem , Nascimento Prematuro/epidemiologia , Adolescente , Recém-Nascido de Baixo Peso , Recém-Nascido , Infecções por Chlamydia/epidemiologia , Infecções por Chlamydia/diagnóstico , Mycoplasma genitalium/isolamento & purificação , Herpes Genital/epidemiologia , Herpes Genital/complicações , Prevalência , Modelos Logísticos , Trichomonas vaginalis/isolamento & purificação , Herpesvirus Humano 2/isolamento & purificação , Cuidado Pré-Natal , Vaginite por Trichomonas/epidemiologia , Vaginite por Trichomonas/diagnóstico
19.
Genes (Basel) ; 15(4)2024 04 08.
Artigo em Inglês | MEDLINE | ID: mdl-38674404

RESUMO

Mycoplasma genitalium (M. genitalium) poses a significant public health challenge due to its association with non-gonococcal urethritis (particularly in men) and antimicrobial resistance. However, despite the prevalence of M. genitalium infections and the rise in resistance rates, routine testing and surveillance remain limited. This is the first study from Croatia that aimed to assess the prevalence and trends of resistance in M. genitalium strains isolated from male individuals by detecting macrolide and fluoroquinolone resistance genes. The study also aimed to explore the factors associated with resistance and changes in resistance patterns over time. Urine samples collected from male individuals in the Zagreb County and northwest region of Croatia between 2018 and 2023 were tested for M. genitalium with the use of molecular methods. Positive samples were subjected to DNA extraction and multiplex tandem polymerase chain reaction (MT-PCR) targeting genetic mutations associated with macrolide (23S rRNA gene) and fluoroquinolone (parC gene) resistance. Of the 8073 urine samples tested from 6480 male individuals (and following the exclusion of repeated specimens), we found that the prevalence of M. genitalium infection was 2.2%. Macrolide resistance was observed in 60.4% of strains, while fluoroquinolone resistance was found in 19.2%. Co-resistance to both antibiotics was present in 18.2% of cases. A statistically significant increase in fluoroquinolone resistance was noted over the study period (p = 0.010), but this was not evident for azithromycin resistance (p = 0.165). There were no statistically significant differences in resistance patterns between age groups, whereas re-testing of patients revealed dynamic changes in resistance profiles over time. The high burden of macrolide resistance and increasing fluoroquinolone resistance underscore the urgent need for comprehensive resistance testing and surveillance programs. The implementation of resistance-guided treatment strategies, along with enhanced access to molecular diagnostics, is pivotal for effectively managing M. genitalium infections.


Assuntos
Antibacterianos , Farmacorresistência Bacteriana , Fluoroquinolonas , Macrolídeos , Infecções por Mycoplasma , Mycoplasma genitalium , Mycoplasma genitalium/genética , Mycoplasma genitalium/efeitos dos fármacos , Mycoplasma genitalium/isolamento & purificação , Humanos , Masculino , Fluoroquinolonas/farmacologia , Fluoroquinolonas/uso terapêutico , Croácia/epidemiologia , Macrolídeos/farmacologia , Macrolídeos/uso terapêutico , Adulto , Infecções por Mycoplasma/microbiologia , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/urina , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Farmacorresistência Bacteriana/genética , Pessoa de Meia-Idade , Adulto Jovem , RNA Ribossômico 23S/genética , Adolescente , Uretrite/microbiologia , Uretrite/epidemiologia , Uretrite/tratamento farmacológico , Testes de Sensibilidade Microbiana
20.
Sex Transm Dis ; 51(7): 493-498, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38602771

RESUMO

BACKGROUND: Mycoplasma genitalium is a major contributor to persistent/recurrent urethritis cases. However, there are limited published studies on recent trends of persistent/recurrent urethritis. METHODS: A retrospective analysis was conducted of men presenting with symptomatic urethritis in 16 sexually transmitted disease (STD) clinics from 2015 to 2019. Poisson regression was used to assess trends in the annual proportions of urethritis episodes with follow-up (FU) characterized with persistent/recurrent urethritis symptoms. Results were also stratified by results of chlamydia (CT) and gonorrhea (NG) testing and treatment prescribed. RESULTS: There were 99,897 urethritis episodes, from 67,546 unique men. The proportion of episodes with persistent/recurrent symptomatic FU visits increased 50.8% over a 4-year period (annual percentage change [APC], 11.3%; 95% confidence interval [CI], 6.5-16.3). Similar trends were observed in nonchlamydial nongonococcal urethritis episodes (APC, 12.7%; 95% CI, 6.8-18.9) but increases among those positive for NG (APC, 12.1%; 95% CI, -2.3 to -28.5) or for CT (APC, 7.3%; 95% CI, -6.7 to 23.5) were not statistically significant. Among episodes who received azithromycin as first-line treatment, increases in the proportion of persistent/recurrent FU visits were observed (APC, 12.6%; 95% CI, 8.6-16.7). For episodes where first-line treatment was doxycycline, no significant increases were detected (APC, 4.3%; 95% CI, -0.3 to 9.2). CONCLUSIONS: We found an increase in the proportion of urethritis episodes with persistent or recurrent symptoms over time. Given these observed trends in episodes negative for NG or CT, an etiology not detectable by routine diagnostics was a likely factor in increased persistence, suggesting patients with urethritis may benefit from diagnostic testing for M. genitalium during an initial symptomatic presentation.


Assuntos
Infecções por Mycoplasma , Mycoplasma genitalium , Recidiva , Uretrite , Humanos , Uretrite/tratamento farmacológico , Uretrite/diagnóstico , Uretrite/microbiologia , Uretrite/epidemiologia , Masculino , Mycoplasma genitalium/isolamento & purificação , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/diagnóstico , Infecções por Mycoplasma/epidemiologia , Estudos Retrospectivos , Adulto , Gonorreia/tratamento farmacológico , Gonorreia/diagnóstico , Gonorreia/epidemiologia , Adulto Jovem , Infecções por Chlamydia/tratamento farmacológico , Infecções por Chlamydia/diagnóstico , Infecções por Chlamydia/epidemiologia , Antibacterianos/uso terapêutico , Pessoa de Meia-Idade , Infecções Sexualmente Transmissíveis/tratamento farmacológico , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/epidemiologia , Azitromicina/uso terapêutico , Azitromicina/administração & dosagem , Adolescente , Doxiciclina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA